190 related articles for article (PubMed ID: 37306927)
21. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
22. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
[TBL] [Abstract][Full Text] [Related]
23. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer.
Yuan SQ; Nie RC; Huang YS; Chen YB; Wang SY; Sun XW; Li YF; Liu ZK; Chen YX; Yao YC; Xu Y; Qiu HB; Liang Y; Wang W; Liu ZX; Zhao Q; Xu RH; Zhou ZW; Wang F
Cancer Commun (Lond); 2023 Dec; 43(12):1312-1325. PubMed ID: 37837629
[TBL] [Abstract][Full Text] [Related]
24. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma.
Guan S; Deng G; Sun J; Han Q; Lv Y; Xue T; Ding L; Yang T; Qian N; Dai G
Front Oncol; 2022; 12():926260. PubMed ID: 36081557
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Darrigues L; Pierga JY; Bernard-Tessier A; Bièche I; Silveira AB; Michel M; Loirat D; Cottu P; Cabel L; Dubot C; Geiss R; Ricci F; Vincent-Salomon A; Proudhon C; Bidard FC
Breast Cancer Res; 2021 Mar; 23(1):31. PubMed ID: 33676547
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.
Lu J; Feng Y; Guo K; Sun L; Ruan S; Zhang K
J Cancer Res Clin Oncol; 2024 Jan; 150(1):25. PubMed ID: 38252173
[TBL] [Abstract][Full Text] [Related]
28. Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence.
Isaksson S; George AM; Jönsson M; Cirenajwis H; Jönsson P; Bendahl PO; Brunnström H; Staaf J; Saal LH; Planck M
Acta Oncol; 2019 Aug; 58(8):1079-1086. PubMed ID: 31230502
[No Abstract] [Full Text] [Related]
29. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
30. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases.
Baumgartner JM; Riviere P; Lanman RB; Kelly KJ; Veerapong J; Lowy AM; Kurzrock R
Ann Surg Oncol; 2020 Sep; 27(9):3259-3267. PubMed ID: 32767050
[TBL] [Abstract][Full Text] [Related]
32. Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study.
Fu R; Huang J; Tian X; Liang C; Xiong Y; Zhang JT; Jiang B; Dong S; Gong Y; Gao W; Li F; Shi Y; Liu Z; Gao X; Chen R; Zhong W; Zhang Y
Mol Oncol; 2023 May; 17(5):825-838. PubMed ID: 36732646
[TBL] [Abstract][Full Text] [Related]
33. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
[TBL] [Abstract][Full Text] [Related]
34. Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer.
Chao A; Chen SJ; Chen HC; Tan KT; Hsiao W; Jung SM; Yang LY; Huang KG; Chou HH; Huang HJ; Chang TC; Chao AS; Lee YH; Wu RC; Lai CH
Biomed J; 2023 Oct; 46(5):100563. PubMed ID: 36208860
[TBL] [Abstract][Full Text] [Related]
35. The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients.
Ottestad AL; Wahl SGF; Grønberg BH; Skorpen F; Dai HY
Exp Mol Pathol; 2020 Feb; 112():104347. PubMed ID: 31759951
[TBL] [Abstract][Full Text] [Related]
36. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
37. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.
Zhang J; Zhou N; Deng H; Chen X; Chen Q; Wang Q; Sun L; Wen Y; Cao X; Luo Z; Zhang J; Zhu W; Guo L
Lung Cancer; 2023 Apr; 178():11-19. PubMed ID: 36758321
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
Wislez M; Domblides C; Greillier L; Mazières J; Monnet I; Kiakouama-Maleka L; Quantin X; Spano JP; Ricordel C; Fraisse P; Janicot H; Audigier-Valette C; Amour E; Langlais A; Rabbe N; Makinson A; Cadranel J; Laurent-Puig P; Lavolé A; Blons H
Lung Cancer; 2021 Jul; 157():124-130. PubMed ID: 34016488
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Fan G; Zhang K; Ding J; Li J
Oncotarget; 2017 May; 8(20):33922-33932. PubMed ID: 28430611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
